Cell-signaling pathways statistically significantly enriched in peripheral blood mononuclear cells of patients who achieved a CR or PR at day 28 on study
| Term . | Odds ratio . | Combined score . | Adjusted P . | Genes . |
|---|---|---|---|---|
| ErbB1 (EGFR) downstream signaling | 76.19 | 1198.70 | <.001 | MAP2K4;MEF2C;RPS6KA5;STAT1 |
| IL-27–mediated signaling events | 153.85 | 1466.11 | .01 | STAT1;STAT2 |
| Trk receptor signaling mediated by the MAPK pathway | 117.65 | 1057.17 | .01 | MEF2C;RPS6KA5 |
| Signaling mediated by p38-α and p38-β | 105.26 | 922.25 | .01 | MEF2C;RPS6KA5 |
| RhoA signaling pathway | 88.89 | 748.53 | .01 | MAP2K4;ROCK2 |
| IL-6–mediated signaling events | 86.96 | 728.41 | .01 | MAP2K4;STAT1 |
| Signaling events mediated by focal adhesion kinase | 68.97 | 545.64 | .01 | MAP2K4;ROCK2 |
| CXCR4-mediated signaling events | 40.00 | 273.05 | .03 | STAT1;STAT2 |
| PDGFR-β signaling pathway | 31.25 | 198.05 | .04 | MAP2K4;STAT1 |
| Term . | Odds ratio . | Combined score . | Adjusted P . | Genes . |
|---|---|---|---|---|
| ErbB1 (EGFR) downstream signaling | 76.19 | 1198.70 | <.001 | MAP2K4;MEF2C;RPS6KA5;STAT1 |
| IL-27–mediated signaling events | 153.85 | 1466.11 | .01 | STAT1;STAT2 |
| Trk receptor signaling mediated by the MAPK pathway | 117.65 | 1057.17 | .01 | MEF2C;RPS6KA5 |
| Signaling mediated by p38-α and p38-β | 105.26 | 922.25 | .01 | MEF2C;RPS6KA5 |
| RhoA signaling pathway | 88.89 | 748.53 | .01 | MAP2K4;ROCK2 |
| IL-6–mediated signaling events | 86.96 | 728.41 | .01 | MAP2K4;STAT1 |
| Signaling events mediated by focal adhesion kinase | 68.97 | 545.64 | .01 | MAP2K4;ROCK2 |
| CXCR4-mediated signaling events | 40.00 | 273.05 | .03 | STAT1;STAT2 |
| PDGFR-β signaling pathway | 31.25 | 198.05 | .04 | MAP2K4;STAT1 |
IL, interleukin; PDGFR-β, platelet-derived growth factor receptor-β.